RealTimeTouch.com RealTimeTouch.com Patent US9639150 RealTimeTouch.com message RealTimeTouch.com RealTimeTouch.com



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




RealTimeTouch.com RealTimeTouch.com Patent US9639150 RealTimeTouch.com message RealTimeTouch.com RealTimeTouch.com
  

Selecta Biosciences Inc patents

Recent patent applications related to Selecta Biosciences Inc. Selecta Biosciences Inc is listed as an Agent/Assignee. Note: Selecta Biosciences Inc may have other listings under different names/spellings. We're not affiliated with Selecta Biosciences Inc, we're just tracking patents.

ARCHIVE: New 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "S" | Selecta Biosciences Inc-related inventors




Date Selecta Biosciences Inc patents (updated weekly) - BOOKMARK this page
09/29/16Tolerogenic synthetic nanocarriers for allergy therapy
09/08/16Tolerogenic synthetic nanocarriers to reduce immune responses to therapeutic proteins
08/25/16Tolerogenic synthetic nanocarriers
08/04/16Tolerogenic synthetic nanocarriers to reduce immune responses to therapeutic proteins
05/12/16Methods and compositions related to the use of low hlb surfactants in the production of synthetic nanocarriers comprising a rapalog
05/12/16Methods and compositions related to synthetic nanocarriers with rapamycin in a stable, super-saturated state
03/17/16Methods and compositions for attenuating exon skipping anti-viral transfer vector immune responses
03/17/16Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses
03/17/16Methods and compositions for attenuating gene therapy anti-viral transfer vector immune responses
03/17/16Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses
03/10/16Methods and compositions for attenuating anti-viral transfer vector immune responses
02/04/16Tolerogenic synthetic nanocarriers for allergy therapy
02/04/16Tolerogenic synthetic nanocarriers for generating cd8+ regulatory t cells
01/28/16Tolerogenic synthetic nanocarriers to reduce cytotoxic t lymphocyte responses
12/31/15Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors
12/17/15Tolerogenic synthetic nanocarriers for t-cell-mediated autoimmune disease
11/26/15Tolerogenic synthetic nanocarriers to reduce immune responses to therapeutic proteins
11/19/15Immunomodulatory agent-polymeric compounds
11/19/15Dose selection of adjuvanted synthetic nanocarriers
11/19/15Tolerogenic synthetic nanocarriers
11/12/15Tolerogenic synthetic nanocarriers to reduce antibody responses
11/12/15Controlled release of immunosuppressants from synthetic nanocarriers
11/12/15Tolerogenic synthetic nanocarriers for inducing regulatory b cells
11/12/15Tolerogenic synthetic nanocarriers for antigen-specific deletion of t effector cells
12/04/14Repeated administration of non-immunosuppressive antigen specific immunotherapeutics
11/13/14Methods and compositions for enhancing cd4+ regulatory t cells
11/06/14Tolerogenic synthetic nanocarriers and therapeutic macromolecules for reduced or enhanced pharmacodynamic effects
11/06/14Tolerogenic synthetic nanocarriers to reduce or prevent anaphylaxis in response to a non-allergenic antigen
11/06/14Local, concomitant administration of tolerogenic synthetic nanocarriers to reduce type i and type iv hypersensitivity
11/06/14Dosing combinations for reducing undesired humoral immune responses
11/06/14Delivery of immunosuppressants having a specified pharmacodynamic effective-life and antigen for the induction of immune tolerance
08/28/14Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
07/17/14Tolerogenic synthetic nanocarriers for inducing regulatory b cells
07/10/14Immunomodulatory agent-polymeric compounds
01/30/14Targeted synthetic nanocarriers with ph sensitive release of immunostimulatory agents
03/07/13Therapeutic protein-specific induced tolerogenic dendritic cells and methods of use
03/07/13Transplantable graft-specific induced tolerogenic dendritic cells and methods of use
03/07/13Dendritic cell subsets for generating induced tolerogenic dendritic cells and related compositions and methods
03/07/13Induced tolerogenic dendritic cells for generating cd8+ regulatory t cells
03/07/13Induced tolerogenic dendritic cells to reduce systemic inflammatory cytokines
03/07/13Antigen-specific induced tolerogenic dendritic cells to reduce cytotoxic t lymphocyte responses
03/07/13Antigen-specific induced tolerogenic dendritic cells to reduce antibody responses
03/07/13Allergen-specific induced tolerogenic dendritic cells for allergy therapy
03/07/13Compositions and methods related to induced tolerogenic dendritic cells externally loaded with mhc class i-restricted epitopes
03/07/13Induced tolerogenic dendritic cells for inducing regulatory b cells
03/07/13Compositions and methods for producing antigen-specific induced tolerogenic dendritic cells with synthetic nanocarriers
02/14/13Control of antibody responses to synthetic nanocarriers
02/14/13Use of nitrocarboxylic acids for the treatment, diagnosis and prophylaxis of aggressive healing patterns
01/31/13Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents
01/31/13Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses
11/29/12Controlled release of immunosuppressants from synthetic nanocarriers
11/29/12Tolerogenic synthetic nanocarriers coupled to cd1d-restricted antigens and methods of use
11/22/12Tolerogenic synthetic nanocarriers for allergy therapy
11/01/12Tolerogenic synthetic nanocarriers to reduce immune responses to therapeutic proteins
11/01/12Tolerogenic synthetic nanocarriers for inducing regulatory b cells
11/01/12Tolerogenic synthetic nanocarriers for antigen-specific deletion of t effector cells
11/01/12Tolerogenic synthetic nanocarriers for generating cd8+ regulatory t cells
11/01/12Tolerogenic synthetic nanocarrier compositions with transplantable graft antigens and methods of use
11/01/12Tolerogenic synthetic nanocarriers to reduce antibody responses
11/01/12Tolerogenic synthetic nanocarriers to reduce cytotoxic t lymphocyte responses
11/01/12Tolerogenic synthetic nanocarriers
11/01/12Tolerogenic synthetic nanocarriers for regulating innate immune responses
09/27/12Osmotic mediated release synthetic nanocarriers
07/12/12Compositions comprising immunostimulatory nucleic acids and related methods
07/05/12Synthetic nanocarriers with reactive groups that release biologically active agents
Patent Packs
05/10/12Modified nicotinic compounds and related methods
03/22/12Targeted multi-epitope dosage forms for induction of an immune response to antigens
03/15/12Synthetic nanocarrier vaccines comprising peptides obtained or derived from human influenza a virus hemagglutinin
03/08/12Synthetic nanocarrier vaccines comprising proteins obtained or derived from human influenza a virus hemagglutinin
03/08/12Synthetic nanocarrier vaccines comprising peptides obtained or derived from human influenza a virus m2e
02/02/12Dose selection of adjuvanted synthetic nanocarriers
12/01/11Nanocarrier compositions with uncoupled adjuvant
12/01/11Multivalent synthetic nanocarrier vaccines
12/01/11Synthetic nanocarrier combination vaccines
11/10/11Eccentric vessels
10/27/11Emulsions and methods of making nanocarriers
09/15/11Immunonanotherapeutics providing a th1-biased response
07/14/11Synthetic virus-like particles conjugated to human papillomavirus capsid peptides for use as vaccines
05/12/11Compositions that induce t cell help
02/03/11Immunomodulatory agent-polymeric compounds
Patent Packs
01/27/11Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
12/02/10Nanocarriers possessing components with different rates of release







ARCHIVE: New 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Selecta Biosciences Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Selecta Biosciences Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###




';